[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR127728A1 - NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1 - Google Patents

NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1

Info

Publication number
AR127728A1
AR127728A1 ARP220103195A ARP220103195A AR127728A1 AR 127728 A1 AR127728 A1 AR 127728A1 AR P220103195 A ARP220103195 A AR P220103195A AR P220103195 A ARP220103195 A AR P220103195A AR 127728 A1 AR127728 A1 AR 127728A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
proteins
fusion protein
protein specific
new fusion
Prior art date
Application number
ARP220103195A
Other languages
Spanish (es)
Inventor
Marina Pavlidou
Kastresana Aizea Morales
Karoline Utschick
Benjamin Weiche
Lucia Pattarini
Catherine Gallou-Harnois
Original Assignee
Pieris Pharmaceuticals Gmbh
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Servier Lab filed Critical Pieris Pharmaceuticals Gmbh
Publication of AR127728A1 publication Critical patent/AR127728A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción proporciona proteínas de fusión específicas tanto para OX40 como para PD-L1, en donde dichas proteínas pueden ser utilizadas para coestimular la activación de linfocitos de una manera dependiente de la diana PD-L1. Dichas proteínas de fusión pueden ser utilizadas en muchas aplicaciones farmacéuticas, por ejemplo como agentes anticáncer y/o moduladores inmunitarios. La presente descripción también se relaciona con métodos de preparación de las proteínas de fusión descriptas en la presente, así como con composiciones que comprenden dichas proteínas de fusión. La presente descripción se relaciona adicionalmente con moléculas de ácido nucleico que codifican dichas proteínas de fusión. Además, la solicitud describe usos terapéuticos y/o diagnóstico de dichas proteínas.The description provides fusion proteins specific for both OX40 and PD-L1, where said proteins can be used to costimulate lymphocyte activation in a manner dependent on the PD-L1 target. Such fusion proteins can be used in many pharmaceutical applications, for example as anticancer agents and/or immune modulators. The present description also relates to methods of preparing the fusion proteins described herein, as well as to compositions comprising said fusion proteins. The present disclosure further relates to nucleic acid molecules encoding said fusion proteins. Furthermore, the application describes therapeutic and/or diagnostic uses of said proteins.

ARP220103195A 2021-11-19 2022-11-18 NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1 AR127728A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21306614 2021-11-19

Publications (1)

Publication Number Publication Date
AR127728A1 true AR127728A1 (en) 2024-02-21

Family

ID=78821243

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103195A AR127728A1 (en) 2021-11-19 2022-11-18 NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1

Country Status (3)

Country Link
AR (1) AR127728A1 (en)
TW (1) TW202334203A (en)
WO (1) WO2023089079A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
BR112018013911A2 (en) * 2016-01-11 2018-12-18 Inhibrx, Inc. multivalent and multispecific ox40 binding fusion proteins
BR112020013133A2 (en) * 2017-12-29 2020-12-08 Ap Biosciences, Inc. MONOSPECIFIC AND BISPECIFIC PROTEINS WITH REGULATION OF THE IMMUNE CHECK POINT FOR CANCER THERAPY
JP2022553176A (en) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 OX40/PD-L1 bispecific antibody

Also Published As

Publication number Publication date
WO2023089079A1 (en) 2023-05-25
TW202334203A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CL2021000207A1 (en) New fusion proteins specific for cd137 and pd-l1
Freyermuth-Trujillo et al. Inflammation: a target for treatment in spinal cord injury
MX2021010039A (en) Novel fusion proteins specific for cd137 and gpc3.
BR112022014623A2 (en) ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF
CL2017002767A1 (en) New specific proteins for cd137.
EP4378962A3 (en) Anti-cancer fusion polypeptide
BR112018068189A2 (en) inducible binding proteins and methods of use
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112021005769A2 (en) dll3 binding proteins and methods of use
BR112018072485A2 (en) bispecific binding proteins and uses thereof
BR112017020445A2 (en) fusion polypeptide, nucleic acid molecule, host cell, method of producing a fusion polypeptide, use of fusion polypeptide, method for activating signaling pathways, method for co-stimulating cells, method for inducing lymphocyte proliferation, and method for direct cd137 collation
BR112018016281A2 (en) protease activatable bispecific t-cell activating molecule, idiotype-specific polypeptide, pharmaceutical composition, uses of the bispecific molecule and method of treating a disease in an individual
ECSP17061751A (en) NEW SPECIFIC PROTEINS FOR PIOVERDIN AND PIOQUELIN
BR112022004047A2 (en) Multispecific binding proteins for cancer treatment
BR112013019975A2 (en) "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell"
UY33319A (en) PROTEINS THAT JOIN TNF-a
MX2019014397A (en) Polypeptides binding adamts5, mmp13 and aggrecan.
AR112069A1 (en) IMMUNOGLOBULINS THAT BIND AGGRECAN
CO2020000369A2 (en) Polypeptides that bind to the complement component c5 or serum albumin and their fusion proteins
MX2021000421A (en) METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR THE TREATMENT OF CANCER.
BR112022021469A2 (en) BIFUNCTIONAL MOLECULES AND METHODS OF USING THEM
BR112022008201A2 (en) SURFACE PROTEIN DEGRADATION USING B-SPECIFIC BINDING AGENT
MX2022001682A (en) Novel antigen binding molecule formats.
BR112018075222A2 (en) anti-tnfrsf25 antibodies
AR127728A1 (en) NEW FUSION PROTEIN SPECIFIC FOR OX40 AND PD-L1

Legal Events

Date Code Title Description
FB Suspension of granting procedure